News & Videos - ALNYLAM PHARMACEUTICALS INC.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire NEW YORK, March 11, 2024 NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Alnylam and...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire NEW YORK, March 3, 2024 NEW YORK , March 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Alnylam and...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire NEW YORK, Nov. 3, 2023 NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Alnylam and certain...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire NEW YORK, Oct. 25, 2023 NEW YORK , Oct. 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Alnylam and...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire NEW YORK, Oct. 17, 2023 NEW YORK , Oct. 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Alnylam and...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights. “The second quarter of 2023 was a very productive one at Alnylam, with commercial execution delivering 43% year-over-year growth in net product revenues, supported by the strong ongoing launch of AMVUTTRA,” said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam....

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 43 rd Annual Growth Conference on Thursday, August 10, 2023 at 10:30 am ET at the InterContinental Hotel in Boston. A live audio webcast of the presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events . A replay will be available on the Alnylam website within 48 hours after...

Alnylam Pharmaceuticals, Inc. (Nasdaq : ALNY), société leader des thérapies iARN, a annoncé aujourd’hui avoir conclu un accord stratégique avec Roche visant à développer et commercialiser le zilebesiran, l’iARN thérapeutique expérimental d’Alnylam pour le traitement de l’hypertension, qui est actuellement en phase 2 de développement. Ce partenariat permet un plan de développement audacieux dans le but de révolutionner le traitement de l’hypertension à l’échelle mondiale...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has entered into a strategic agreement with Roche to develop and commercialize zilebesiran, Alnylam’s investigational RNAi therapeutic for the treatment of hypertension, which is currently in Phase 2 of development. The partnership allows for a bold development plan with the goal of disrupting the hypertension treatment paradigm globally while advancing Alnylam’s P 5 x25 strategy. Roche...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2023 on Thursday, August 3, 2023, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2023 results as well as expectations for the future via conference call on Thursday, August 3, 2023 at 8:30 am ET. To access the call, please register online at...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), leader des traitements basés sur le mécanisme d’interférence ARNi, a annoncé aujourd’hui que les résultats de son étude de phase 1 de zileberisan, un traitement ARNi expérimental ciblant l'angiotensinogène hépatique pour le développement d'un traitement de l'hypertension, ont été publiés dans le New England Journal of Medicine (NEJM) . L'article complet est intitulé « Zilebesiran, an RNA Interference Therapeutic Agent for...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today updated positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA). The results were presented at the 2023 Alzheimer’s Association International Conference (AAIC) being held July 16-20, 2023 in Amsterdam, The...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has set a date of September 13, 2023 for the meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the supplemental New Drug Application for patisiran, an investigational treatment for the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis. As previously announced, the FDA has set an action date of October 8, 2023...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 44 th Annual Global Healthcare Conference on Monday, June 12, 2023 at 8:00 am PT (11:00 am ET) at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. A live audio webcast of the presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events . A replay will be available...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights. “The first quarter of 2023 saw continued strong commercial execution, driven by the ongoing launch of AMVUTTRA, delivering robust 48% growth in total product sales compared with the first quarter 2022. We also made significant progress with our broad pipeline, delivering...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 1:40 pm PT (4:40 pm ET) at the Encore Hotel in Las Vegas. A live audio webcast of the presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events . A replay will be available on the Alnylam website within 48 hours after...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report . This year’s edition reasserts our commitment to advancing pioneering RNAi science and supporting health equity. The company continues to take meaningful steps across each of our six corporate responsibility pillars to ensure everyone has access to essential health services and medicines. As the company further these efforts, it will regularly...

Alnylam Pharmaceuticals, Inc. (Nasdaq : ALNY) et Regeneron Pharmaceuticals, Inc. (Nasdaq : REGN) ont annoncé aujourd’hui des résultats provisoires positifs du volet à dose unique ascendante en cours de l’étude de Phase 1 évaluant ALN-APP, un iARN expérimental ciblant la protéine précurseur de l'amyloïde (APP) en développement pour le traitement de la maladie d’Alzheimer et de l’angiopathie amyloïde cérébrale (AAC). Vingt patients ont été recrutés dans trois groupes à...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive interim results from the ongoing single ascending dose part of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA). Twenty patients have been enrolled in three single-dose cohorts in Part A of the ongoing Phase 1 study in...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2023 on Thursday, May 4, 2023, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2023 results as well as expectations for the future via conference call on Thursday, May 4, 2023 at 8:30 am ET. To access the call, please register online at...